Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2008.12.019
Title: Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
Authors: Zeuzem, S.
Gane, E.
Liaw, Y.-F.
Lim, S.G. 
DiBisceglie, A.
Buti, M.
Chutaputti, A.
Rasenack, J.
Hou, J.
O'Brien, C.
Nguyen, T.T.
Jia, J.
Poynard, T.
Belanger, B.
Bao, W.
Naoumov, N.V.
Keywords: Chronic hepatitis B
GLOBE trial
Lamivudine
Predictors
Telbivudine
Issue Date: Jul-2009
Source: Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V. (2009-07). Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. Journal of Hepatology 51 (1) : 11-20. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2008.12.019
Abstract: Background/Aims: In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2 years. We analyzed all telbivudine recipients in this trial to determine the predictors of optimal outcomes. Methods: The intent-to-treat population comprised 458 HBeAg-positive and 222 HBeAg-negative telbivudine-treated patients. Multivariate logistic regression analyses were employed to evaluate baseline and/or early on-treatment variables. Results: Baseline HBV DNA < 9 log10 copies/mL, or ALT levels ≥2× above normal were strong pretreatment predictors for HBeAg-positive, but not for HBeAg-negative patients. However, non-detectable serum HBV DNA at treatment week 24 (TW24) was the strongest predictor for better outcomes for both groups. A combination of pretreatment characteristics plus TW24 response identified subgroups with the best outcomes: (1) HBeAg-positive patients with baseline HBV DNA < 9 log10 copies/mL, ALT ≥ 2× above normal and non-detectable HBV DNA at TW24 achieved at 2 years: non-detectable HBV DNA in 89%, HBeAg seroconversion in 52%, telbivudine resistance in 1.8%; and (2) HBeAg-negative patients with baseline HBV DNA < 7 log10 copies/mL and non-detectable serum HBV DNA at TW24 achieved at 2 years: non-detectable HBV DNA in 91%, telbivudine resistance in 2.3%. Conclusion: During telbivudine treatment, non-detectable serum HBV DNA at treatment week 24 is the strongest predictor for optimal outcomes at 2 years. © 2009 European Association for the Study of the Liver.
Source Title: Journal of Hepatology
URI: http://scholarbank.nus.edu.sg/handle/10635/129754
ISSN: 01688278
DOI: 10.1016/j.jhep.2008.12.019
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

153
checked on Feb 13, 2018

WEB OF SCIENCETM
Citations

133
checked on Jan 15, 2018

Page view(s)

6
checked on Feb 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.